| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Aminolevulinic acid (5-ALA) is primarily known for its role as a biosynthetic precursor to heme 5-ALA — 5-aminolevulinic acid (5-aminolevulinic acid; often administered as the hydrochloride salt) is an endogenous, small-molecule heme biosynthesis precursor used clinically as a pro-photosensitizer for tumor visualization and, when paired with an appropriate light source, photodynamic therapy (PDT). It is formally a drug/prodrug modality whose functional identity is to drive intracellular accumulation of the fluorescent porphyrin protoporphyrin IX (PpIX), enabling fluorescence-guided resection (notably high-grade glioma) and light-activated cytotoxicity in appropriately illuminated tissues. Standard abbreviations include 5-ALA, ALA; the key active photochemical mediator is PpIX. Tumor selectivity is primarily metabolic (differential porphyrin/heme pathway handling), rather than target-receptor binding, and clinical performance is strongly constrained by light penetration and local oxygen availability. Primary mechanisms (ranked):
Bioavailability / PK relevance: Route-locked. Oral ALA-HCl is used for intraoperative fluorescence in glioma with timed dosing prior to anesthesia/surgery; topical formulations are used for dermatologic PDT with local incubation followed by office-based illumination. Systemic exposure is clinically relevant for oral use (and photosensitivity risk), while topical use is primarily local with workflow defined by incubation + illumination. In-vitro vs systemic exposure relevance: Many “dark” in-vitro ALA studies use concentrations that are not directly exposure-matched to clinical plasma levels; the clinically dominant cytotoxic mechanism is typically light-triggered, PpIX-mediated photochemistry rather than concentration-only pharmacology. Clinical evidence status: Established clinical deployment as an adjunct optical imaging agent for fluorescence-guided resection of suspected high-grade glioma (approved) and as a photosensitizer precursor for dermatologic PDT (approved for actinic keratosis; additional indications vary by jurisdiction). Oncology PDT applications beyond these settings are heterogeneous and commonly investigational or center-specific. -ALA is used in medical therapies such as photodynamic therapy (PDT) for certain types of cancer and skin conditions.- Inside the cells, ALA enters the heme biosynthetic pathway and is converted to protoporphyrin IX (PpIX), a potent photosensitizer. -The light activates the accumulated PpIX, leading to the production of reactive oxygen species (ROS). -FDA approved June 2017 as a photo-imaging tool during neurosurgery for malignant glioma. The patient takes an oral dose of Gleolan 3 hours before surgery. Mechanistic pathway ranking for 5-ALA (oncology focus)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Source: |
| Type: |
| Also known as CP32. Cysteinyl aspartate specific proteinase-3 (Caspase-3) is a common key protein in the apoptosis and pyroptosis pathways, and when activated, the expression level of tumor suppressor gene Gasdermin E (GSDME) determines the mechanism of tumor cell death. As a key protein of apoptosis, caspase-3 can also cleave GSDME and induce pyroptosis. Loss of caspase activity is an important cause of tumor progression. Many anticancer strategies rely on the promotion of apoptosis in cancer cells as a means to shrink tumors. Crucial for apoptotic function are executioner caspases, most notably caspase-3, that proteolyze a variety of proteins, inducing cell death. Paradoxically, overexpression of procaspase-3 (PC-3), the low-activity zymogen precursor to caspase-3, has been reported in a variety of cancer types. Until recently, this counterintuitive overexpression of a pro-apoptotic protein in cancer has been puzzling. Recent studies suggest subapoptotic caspase-3 activity may promote oncogenic transformation, a possible explanation for the enigmatic overexpression of PC-3. Herein, the overexpression of PC-3 in cancer and its mechanistic basis is reviewed; collectively, the data suggest the potential for exploitation of PC-3 overexpression with PC-3 activators as a targeted anticancer strategy. Caspase 3 is the main effector caspase and has a key role in apoptosis. In many types of cancer, including breast, lung, and colon cancer, caspase-3 expression is reduced or absent. On the other hand, some studies have shown that high levels of caspase-3 expression can be associated with a better prognosis in certain types of cancer, such as breast cancer. This suggests that caspase-3 may play a role in the elimination of cancer cells, and that therapies aimed at activating caspase-3 may be effective in treating certain types of cancer. Procaspase-3 is a apoptotic marker protein. Prognostic significance: • High Cas3 expression: Associated with good prognosis and increased sensitivity to chemotherapy in breast, gastric, lung, and pancreatic cancers. • Low Cas3 expression: Linked to poor prognosis and increased risk of recurrence in colorectal, hepatocellular carcinoma, ovarian, and prostate cancers. |
| 3453- | 5-ALA, | The heme precursor 5-aminolevulinic acid disrupts the Warburg effect in tumor cells and induces caspase-dependent apoptosis |
| - | in-vitro, | Lung, | A549 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:332 Target#:42 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid